Siberia’s Vector Research Center has claimed that all volunteers vaccinated by its COVID-19 vaccine, EpiVacCorona, developed antibodies, although the first two phases of testing involved only 100 volunteers. The center reported, “Clinical studies have shown that antibodies were detected in 100% of the volunteers immunized with the EpiVacCorona vaccine, Most of the volunteers vaccinated with the EpiVacCorona vaccine showed induction of a pronounced specific T-cell immune response.”
